Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
GLP Diet is a personalized weight loss app supporting GLP-1 meds with tailored meals, workouts, trackers, and expert guidance for fast and lasting results.
-
Omada Health announces GLP-1 Flex Care, giving employers a new, flexible path to support obesity care
-
Omada Health Reports Fourth Quarter and Full-Year 2025 Results
-
MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.
-
PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes...
-
GLP-1 use up 67% as bariatric surgeries fall 13%; lower annual costs, but long-term benefits and adherence remain uncertain.
-
LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the Company”), the experts in the personalised management of chronic disease, today announces Pinder Sahota has joined the Company as a...
-
Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.
-
Novo Nordisk has filed a lawsuit against telehealth firm Hims & Hers for patent infringement and putting patients’ lives at stake with knockoff drugs.
-
Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app.